Although the sample sizefor this study was too small, it certainly raises an intriguing question as to whethergermline mutations of RUNX1 predispose FPD/AML patients to luminalbreast cancer, but only under a background of either TP53 orRB1 loss. This evidence concerns the gene RUNX1 and cancer.